Page 39 - The Flying Publisher Guide to Hepatitis C Treatment
P. 39

Patients’ monitoring during and after treatment   |   39

                                   Table 2.6  –  Composite biochemical scores
                                   Test           Markers          Interpretation
                                   FibroTest™     alpha-2-macroglobulin, Result is provided as a score of 0
                                   (Imbert-Bismut 2001)  apolipoprotein A1,  to 1, proportional to the severity
                                                  haptoglobin, GGT,  of the fibrosis, with conversion
                                                                   to the METAVIR system (from F0
                                                   bilirubin       to F4).
                                   HepaScore™     alpha 2 -macroglobulin A HepaScore <0.55 is considered
                                   (Adams 2005)   GGT*, bilirubin,  “negative” and indicates a
                                                  hyaluronic acid, age,  METAVIR score of F0 or F1.
                                                  gender           A HepaScore ≥0.55 is considered
                                                                   “positive” and indicates a
                                                                   METAVIR score of F2 to F4.
                                   FibroMeter™     alpha2–macroglobulin, FibroMeter™ has two main
                                   (Cales 2005)   hyaluronic acid,  diagnostic targets (fibrosis stage
                                                  platelets, prothrombin and area of fibrosis), being
                                                  index, AST, urea, age,  adapted for special explicit
                                                  gender           causes†.
                                   * GGT: γ-glutamyltranspeptidase
                                   † chronic viral hepatitis B or C, alcoholic liver disease and non-alcoholic fatty
                                   liver disease
                                   FibroTest™ (Biopredictive, Paris, France) identifies about 70% of
                                   patients with histological signs of moderate to severe fibrosis
                                   and about 90% of patients with histological signs of cirrhosis,
                                   using the manufacturers’ recommended cutoff values. The
                                   FibroTest™ together with FibroScan™ have excellent utility for
                                   the identification of HCV-related cirrhosis, but lesser accuracy
                                   for earlier stages (Shaheen 2007).
                                   All these tests are based on routine biochemistry blood assays
                                   and can be influenced by intercurrent conditions. At the same
                                   time, these scores may fluctuate or revert to lower classes after
                                   initial worsening and a dynamic overview is more valuable than
                                   a single determination.
                                   In Europe, the typical approach is to perform a blood test such as
                                   one of the commercially available assays, followed by transient
                                   elastography. If both tests have concordant results on the
                                   disease stage, no biopsy is needed; if there is discordance, biopsy
                                   is performed. New fibrosis indexes combining the biochemical
   34   35   36   37   38   39   40   41   42   43   44